N/A Completed N=100 Randomized Other

Does the Application of Cold Decreases the Pain Associated in the Pose of a Patch of Capsaicine at High Concentration on the Carrier Patients of Localized Neuropathic Pains ? - DIDOCAP

Localized Neuropathic Pain

Source: ClinicalTrials.gov NCT02869867 ↗

Enrolled (actual)

100

Serious AEs

—

Results posted

Aug 2024

Primary outcomePrimary: Visual Analogue Pain Scale (Burning Pain) — 6.99; 3.78 units on a scale — p=<0.001

Summary

Nursing study, prospective, randomized, two-center open-label. Patients will be randomized into two groups during their first laying Qutenza®: * Patients receiving the laying of Qutenza® without refrigerated cushion * Patients receiving the laying of Qutenza® associated with a refrigerated cushion The objective of the study is to evaluate the effectiveness of the application of cold to the reduction of pain (burning) after one hour of patch installation high concentration capsaicin (Qutenza®) in patients localized neuropathic pain.

Outcome Measures

Outcome	Result	p-value
PRIMARY Visual Analogue Pain Scale (Burning Pain)	6.99; 3.78	<0.001 sig

Eligibility Criteria

Inclusion Criteria

Major
Do not opposing the participation in the study
Monitoring in the case of localized neuropathic pain
Diagnostic with neuropathic pain score ≥ 4
Neuropathic pain conventional treatment failure of first-line
Front advantage of laying a first patch Qutenza®
With ability to understand the proposed study

Exclusion Criteria

Patch Installation on the feet, face, mucous membranes
Eutectic mixture of local anesthetics (EMLA) Pose premedication
Having Already received prior to the installation of a patch of Qutenza®
Allergy to components Qutenza®
Known and poorly stabilized hypertension
Known cryoglobulinaemia
Pregnant or lactating women
Patient enjoying a measure of legal protection (guardianship, guardianship ...)
Private Patient freedom
No affiliation to a social security scheme.
Refusal to participate in the study

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02869867). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.